Imipenem/Cilastatin Kabi (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem inhibits bacterial cell‑wall synthesis by binding to penicillin‑binding proteins, leading to cell lysis. Cilastatin is added to block renal dehydropeptidase I, an enzyme that would otherwise degrade imipenem, thereby preserving its antibacterial activity in the bloodstream.

The dosing regimen for Imipenem/Cilastatin Kabi is individualized by the prescribing clinician based on infection severity, site, renal function and patient weight. Healthcare professionals determine the appropriate dose, infusion rate and treatment duration for each patient.

Safety data for Imipenem/Cilastatin in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, and it should only be used when the potential benefit justifies any potential risk to the fetus or infant. Breastfeeding mothers should consult their physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Imipenem/Cilastatin offers a broad spectrum similar to meropenem and ertapenem but includes cilastatin to protect imipenem from renal degradation, allowing higher and more stable plasma concentrations. Choice among carbapenems depends on local resistance patterns, dosing convenience and specific infection sites.

The product must be stored refrigerated at 2‑8 °C, protected from light, and should not be frozen or shaken. Once reconstituted, the solution should be used within the time frame specified in the product label and kept under the same temperature conditions.

Imipenem/Cilastatin is supplied as a sterile injection solution for intravenous infusion. It is reconstituted with a compatible diluent, then administered over a prescribed period, typically 30 minutes to one hour, depending on the clinical protocol.

The most critical adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders, severe allergic reactions such as anaphylaxis, and Clostridioides difficile‑associated colitis. Prompt recognition and management of these events are essential.

Patients with a known hypersensitivity to imipenem, cilastatin, or any other beta‑lactam antibiotics should avoid this medication. Additionally, individuals with severe renal dysfunction require dose adjustment, and those with uncontrolled epilepsy may be at higher risk for seizure‑related complications.